Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venetoclax + olverembatinib + prednisone
- Development stage
- Unknown
- Lead developer
- Ascentage Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Venetoclax + olverembatinib + prednisone, also known as the VOP regimen, is a combination therapy being evaluated for the treatment of Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (B-ALL). The regimen combines three distinct therapeutic agents: olverembatinib (HQP1351), a third-generation BCR-ABL tyrosine kinase inhibitor (TKI) designed to overcome resistance mutations like T315I; venetoclax, a selective BCL-2 inhibitor that promotes apoptosis in leukemic cells; and prednisone, a glucocorticoid with lymphocytotoxic properties. This combination is specifically being studied in Phase II clinical trials led by the First Affiliated Hospital of Zhejiang University to improve deep molecular response rates and survival outcomes in adult patients with newly diagnosed Ph+ B-ALL, a high-risk subtype of leukemia.
- Other names
- VOP regimenVenetoclax-Olverembatinib-Prednisone
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on venetoclax + olverembatinib + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venetoclax + olverembatinib + prednisone.